Patent application number | Description | Published |
20090131370 | Novel Nucleoside Derivatives - Compounds of Formulae I-XVI, stereoisomers, and pharmaceutically acceptable salts or prodrugs thereof, their preparation, and their uses for the treatment of viral diseases including hepatitis C viral infection, cancer, diabetes, and other diseases are described: formula (I). | 05-21-2009 |
20090192121 | NOVEL BISAMIDATE PHOSPHONATE PRODRUGS - Novel bisamidate phosphonate prodrugs of FBPase inhibitors of the Formula IA: | 07-30-2009 |
20090209481 | Nucleoside prodrugs and uses thereof - Compounds having the formula I or II wherein R | 08-20-2009 |
20100305060 | Nucleoside Prodrugs and Uses Thereof - This application provides compositions or compounds as disclosed herein that are suitable for treating hepatic viral diseases, such as hepatitis C(HCV). | 12-02-2010 |
20110009356 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS - Novel cyclic phosphoramidate prodrugs of drugs of formula I | 01-13-2011 |
20120039845 | NUCLEOSIDE PRODRUGS AND USES THEREOF - Compounds having the formula I or II, wherein R | 02-16-2012 |
20120093729 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS - Novel cyclic phosphoramidate prodrugs of drugs of formula I | 04-19-2012 |
20120214769 | Novel Antagonists of the Glucagon Receptor - The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formula I, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same. | 08-23-2012 |
20120270842 | Inhibitors of Diacylglycerol O-Acyltransferase 1 (DGAT-1) and Uses Thereof - The invention pertains to use of DGAT-1 inhibitors to treat and/or prevent overweight, obesity and various diseases and disorders associated therewith. Other conditions also can be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight patients, those with diabetes or other glucose metabolic disorders such as Syndrome X and/or polycystic ovary disease. Compounds and compositions suitable for use in the disclosed methods are also provided. | 10-25-2012 |
20140356325 | NOVEL 2'-C-METHYL NUCLEOSIDE DERIVATIVE COMPOUNDS - Compositions and methods relating to 2′-C-methyl nucleoside 5′-monophosphate derivative compounds are provided. In some embodiments, the novel compounds are useful to treat viral infections. In particular, 2′-C-methyl nucleoside 5′-monophosphate derivative compounds, stereoisomers, and pharmaceutically acceptable salts or prodrugs thereof, their preparation, and their uses for the treatment of viral infection are described. | 12-04-2014 |